Avalon GloboCare Corp.

Avalon GloboCare Corp. is a commercial-stage company headquartered in Freehold, New Jersey, focused on developing and delivering innovative products and services across consumer health and technology markets. The company has evolved from its historical roots in biotechnology and healthcare services to emphasize precision diagnostics and artificial intelligence solutions.

Its key offerings include the KetoAir™ breathalyzer device, a nanosensor technology for measuring ketosis levels, which is an FDA-registered Class I medical device marketed in North America, South America, the UK, and the European Union. Through its subsidiary, Avalon Quantum AI, the company is advancing next-generation AI systems, including the "Catch-Up" SaaS platform for automated generative AI video creation, designed to produce audience-adaptive commentary video variants. Additionally, Avalon GloboCare provides clinical laboratory services, offering a broad portfolio of diagnostic tests such as drug testing, toxicology, general bloodwork, anatomic pathology, and urine toxicology, partly through its 40% interest in Laboratory Services MSO, LLC.

In recent developments, Avalon GloboCare has strategically pivoted towards artificial intelligence, with its Avalon Quantum AI subsidiary joining the AMD AI Developer Program in May 2026 and collaborating with Caylent and Amazon Web Services on Agentic AI Platform Development in April 2026. The company also filed a third U.S. provisional patent for its Catch-Up Generative AI Video Platform in February 2026 and has regained compliance with Nasdaq stockholders' equity requirements. Leadership includes Ms. Meng Li as Interim CEO & COO, Luisa Ingargiola as Chief Financial Officer, and Mr. Wenzhao Lu as Chairman of the Board.